UTESCH v. LANNETT COMPANY, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedAugust 12, 2021
Docket2:16-cv-05932
StatusUnknown

This text of UTESCH v. LANNETT COMPANY, INC. (UTESCH v. LANNETT COMPANY, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
UTESCH v. LANNETT COMPANY, INC., (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

JOHN UTESCH, et al., CIVIL ACTION Plaintiffs,

v. NO. 16-5932 LANNETT COMPANY, INC., ARTHUR P. BEDROSIAN, MARTIN P. GALVAN, Defendants.

OPINION

In this proposed securities fraud class action against Defendants Lannett Company, Inc., Arthur P. Bedrosian (Lannett’s former chief executive officer) and Martin P. Galvan (its former chief financial officer) (collectively, “Defendants”), Lead Plaintiff University of Puerto Rico Retirement System (“UPRRS”) and Plaintiffs Ironworkers Locals 40, 361, and 417 Union Security Funds (collectively “Plaintiffs”) assert securities fraud claims under Section 10(b) of the Securities Exchange Act of 1934 (“the Exchange Act”) and Rule 10b-5 against all Defendants, and claims against the individual defendants under Section 20(a) of the Exchange Act. See 15 U.S.C. § 78j(b); 17 C.F.R. § 240.10b-5; 15 U.S.C. § 78t(a). Plaintiffs now move to certify a class pursuant to Federal Rules of Civil Procedure 23(a) and (b)(3), to be appointed class representatives, and for the appointment of class counsel. Both Plaintiffs and Defendants seek to exclude the opposing party’s expert report for failure to comply with the standard of Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). For the following reasons, the motions to exclude will be denied and the class certification motion will be granted. I. BACKGROUND AND PROCEDURAL HISTORY During the presented class period – July 15, 2014, to October 31, 2017 – Plaintiffs allege that they purchased Lannett’s common stock at prices that were artificially inflated because of Defendants’ false and misleading statements concerning the pricing of generic drugs and investigations into price-fixing in the generic drug market. Plaintiffs allege that anticompetitive conduct among Lannett’s competitors caused price

increases for five generic drugs which together accounted for most of Lannett’s total annual sales from 2013 to 2016. Lannett publicly disclosed that it received a subpoena and interrogatories from the Connecticut Attorney General in connection with an investigation of anticompetitive conduct in the generic drug industry at the start of the class period in July 2014, and grand jury subpoenas in connection with a federal investigation in November and December 2014. However, say Plaintiffs, “[e]ven as it began to be revealed during the Class Period that several of Lannett’s competitors were implicated in illegal price-fixing and anti-competitive conduct, Defendants assured investors that Lannett’s past financial results were the product of competitive market forces; and, that the Company’s pricing strategy and future results would not be impacted by regulatory scrutiny of anticompetitive conduct in the industry, or the threat of being

implicated in any price-fixing or anticompetitive scheme.” More specifically, Plaintiffs contend that Defendants’ statements during the class period in public regulatory filings, press releases, and by the individual defendants during earnings calls and other public events were materially false or misleading in that: (1) “Defendants misrepresented to Class members that Lannett’s growth was the result of competitive market forces that afforded an opportunity for Lannett’s aggressive pricing campaign,” whereas Lannett’s price increases in actuality were caused by “extensive price-fixing schemes and anticompetitive conduct throughout that generic drug industry that directly implicated Lannett’s competitors in markets for key Lannett products”; (2) “[a]s regulatory scrutiny into price-fixing and anticompetitive conduct increased, Defendants issued a series of misleading statements and omissions of material fact that misled Plaintiffs and Class members regarding the risk that Lannett would be implicated in price-fixing and anticompetitive conduct”; and, (3) Defendants’ statements that the company had complied with the law in the pricing of its products “created the false impression that [] Lannett . . . had

conducted a complete and thorough investigation as to whether Lannett engaged in anticompetitive conduct, and the risk that Lannett would be implicated in an action alleging anticompetitive conduct,” but in actuality Lannett’s “internal investigation was no[t] completed, and had a limited focus.” Throughout the class period, Lannett’s stock price fell as information became public that revealed potential anticompetitive conduct in the generic drug industry and Lannett’s potential exposure to liability. Plaintiffs allege that Lannett’s stock value fell 13% in December 2014 after Lannett disclosed that it had received the federal grand jury subpoenas, and fell 26% following the publication of a Bloomberg article in November 2016 describing the possibility that criminal charges would be filed against pharmaceutical companies, including Lannett. At the close of the

class period, on October 31, 2017, Lannett’s stock price dropped 14% after the Connecticut Attorney General filed a complaint alleging a conspiracy among generic drugs makers, including Lannett, to engage in anticompetitive conduct and price-fixing. Plaintiffs now move to certify the following damages class: All persons and entities who purchased or acquired the publicly traded common stock of Lannett Company, Inc. . . . during the period from July 15, 2014 and October 31, 2017, inclusive[,] . . . and who were damaged thereby. . . .1

1 Excluded from the Class are Defendants, the officers and directors of Lannett, at all relevant times, members of their immediate families and their legal representatives, heirs, successors or assigns and any entity in which Defendants have or had a controlling interest. II. LEGAL STANDARDS “The class-action device is an exception to the rule that litigation is usually conducted by and on behalf of the individual named parties only. Accordingly, the party proposing class- action certification bears the burden of affirmatively demonstrating by a preponderance of the

evidence her compliance with the requirements of Rule 23.” Byrd v. Aaron’s Inc., 784 F.3d 154, 163 (3d Cir. 2015) (quotation marks and citations omitted). To proceed as a certified class action, “every putative class action must satisfy the four requirements of Rule 23(a) and the requirements of either Rule 23(b)(1), (2), or (3).” Marcus v. BMW of N. Am., LLC, 687 F.3d 583, 590 (3d Cir. 2012) (citation omitted). Failure to satisfy any of these requirements precludes certification. Danvers Motor Co. v. Ford Motor Co., 543 F.3d 141, 147 (3d Cir. 2008). “Rule 23 does not set forth a mere pleading standard.” Wal-Mart Stores, Inc. v. Dukes, 564 U.S. 338, 350 (2011). “Rather, a party must not only be prepared to prove that there are in fact sufficiently numerous parties, common questions of law or fact, typicality of claims or defenses, and adequacy of representation, as required by Rule 23(a),” but “must also satisfy

through evidentiary proof at least one of the provisions of Rule 23(b).” Comcast Corp. v. Behrend, 569 U.S. 27, 33 (2013) (quotation marks and citation omitted). “A party’s assurance to the court that it intends or plans to meet the requirements is insufficient.” In re Hydrogen Peroxide Antitrust Litig., 552 F.3d 305, 318 (3d Cir. 2008) (citations omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Schiff
602 F.3d 152 (Third Circuit, 2010)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Kamen v. Kemper Financial Services, Inc.
500 U.S. 90 (Supreme Court, 1991)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
In Re DVI, Inc. Securities Litigation
639 F.3d 623 (Third Circuit, 2011)
Erica P. John Fund, Inc. v. Halliburton Co.
131 S. Ct. 2179 (Supreme Court, 2011)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Lewis v. Curtis
671 F.2d 779 (Third Circuit, 1982)
Hassine v. Jeffes
846 F.2d 169 (Third Circuit, 1988)
Sowell v. Butcher & Singer, Inc.
926 F.2d 289 (Third Circuit, 1991)
In Re Paoli Railroad Yard PCB Litigation
35 F.3d 717 (Third Circuit, 1994)
Schneider v. Fried
320 F.3d 396 (Third Circuit, 2003)
Dewey v. Volkswagen Aktiengesellschaft
681 F.3d 170 (Third Circuit, 2012)
Marcus v. BMW of North America, LLC
687 F.3d 583 (Third Circuit, 2012)
Comcast Corp. v. Behrend
133 S. Ct. 1426 (Supreme Court, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
UTESCH v. LANNETT COMPANY, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/utesch-v-lannett-company-inc-paed-2021.